| Patent application number | Description | Published |
|---|
| 20090062183 | Modulation of synaptogenesis - Soluble proteins, e.g. thrombospondins, can trigger synapse formation. Such proteins are synthesized in vitro and in vivo by astrocytes, which therefore have a role in synaptogenesis. These thrombospondins are only expressed in the normal brain exactly during the period of developmental synaptogenesis, being off in embryonic brain and adult brain but on at high levels in postnatal brain. Methods are provided for protecting or treating an individual suffering from adverse effects of deficits in synaptogenesis, or from undesirably active synaptogenesis. These findings have broad implications for a variety of clinical conditions, including traumatic brain injury, epilepsy, and other conditions where synapses fail to form or form inappropriately. Synaptogenesis is enhanced by contacting neurons with agents that are specific agonists or antagonists of thrombospondins. Conversely, synaptogenesis is inhibited by contacting neurons with inhibitors or antagonists of thrombospondins. | 03-05-2009 |
| 20100087375 | Modulation of synaptogenesis - Soluble proteins, e.g. thrombospondins, can trigger synapse formation. Such proteins are synthesized in vitro and in vivo by astrocytes, which therefore have a role in synaptogenesis. These thrombospondins are only expressed in the normal brain exactly during the period of developmental synaptogenesis, being off in embryonic brain and adult brain but on at high levels in postnatal brain. Methods are provided for protecting or treating an individual suffering from adverse effects of deficits in synaptogenesis, or from undesirably active synaptogenesis. These findings have broad implications for a variety of clinical conditions, including traumatic brain injury, epilepsy, and other conditions where synapses fail to form or form inappropriately. Synaptogenesis is enhanced by contacting neurons with agents that are specific agonists or antagonists of thrombospondins. Conversely, synaptogenesis is inhibited by contacting neurons with inhibitors or antagonists of thrombospondins. | 04-08-2010 |
| 20110112034 | Modulation of synaptogenesis - Soluble proteins, e.g. thrombospondins, can trigger synapse formation. Such proteins are synthesized in vitro and in vivo by astrocytes, which therefore have a role in synaptogenesis. These thrombospondins are only expressed in the normal brain exactly during the period of developmental synaptogenesis, being off in embryonic brain and adult brain but on at high levels in postnatal brain. Methods are provided for protecting or treating an individual suffering from adverse effects of deficits in synaptogenesis, or from undesirably active synaptogenesis. These findings have broad implications for a variety of clinical conditions, including traumatic brain injury, epilepsy, and other conditions where synapses fail to form or form inappropriately. Synaptogenesis is enhanced by contacting neurons with agents that are specific agonists or antagonists of thrombospondins. Conversely, synaptogenesis is inhibited by contacting neurons with inhibitors or antagonists of thrombospondins. | 05-12-2011 |
| Patent application number | Description | Published |
|---|
| 20080262491 | Tuna Device with Integrated Saline Reservoir - Methods and apparatus for ablating a target tissue are discussed. Such methods and apparatus include those that simplify tissue ablation. For example, a tissue ablation device having an actuator, such as a trigger mechanism, coupled to a power source and an electrode is discussed. A single step of engaging the actuator causes the electrode to be introduced into the target tissue and causes energy to be delivered from the power supply to the tissue via the electrode. Devices that include an electrode actuator for causing the electrode to be introduced into the target tissue and a fluid actuator for causing the fluid to flow to the target tissue are also discussed. Methods of causing the electrode to be introduced into the target tissue and fluid to flow to the target tissue with a single step and more than one step are also discussed. | 10-23-2008 |
| 20090276024 | SELF EXPANDING ELECTRODE CUFF - An expandable electrode cuff of an implantable stimulation system that includes a base member, a first flange member extending from a proximal end along a first side wall of the base member to a first distal end, and a second flange member extending from a proximal end along a second side wall of the base member to a second distal end. The first flange member extends over both a top wall of the base member and the second flange member, and the second flange member extends over the top wall to form a lumen. The electrode cuff is capable of being advanced between a first position corresponding to both flange members extending over the top wall, a second position corresponding to the first flange member not extending over the top wall and the second flange member extending over the top wall, and a third position corresponding to both of the flange members not extending over the top wall. | 11-05-2009 |
| 20100217368 | CONTROLLED DETACHMENT OF INTRA-LUMINAL MEDICAL DEVICE - An intra-luminal medical device includes a fixation mechanism to attach the medical device to tissue within a body lumen, and a detachment mechanism to permit selective detachment of the medical device from the tissue attachment site without the need for endoscopic or surgical intervention. An electromagnetic device may be provided to mechanically actuate the detachment mechanism. Alternatively, a fuse link may be electrically blown to detach the medical device. As a further alternative, a rapidly degradable bonding agent may be exposed to a degradation agent to detach the medical device from a bonding surface within the body lumen. The medical device may eliminate problems associated with uncertain and inconsistent detachment of intra-luminal medical devices. | 08-26-2010 |
| 20110060328 | PORTABLE THERAPY DELIVERY DEVICE WITH FLUID DELIVERY - The disclosure describes a system that may be used to deliver a plurality of therapies using one portable device. The system includes a fluid pump that pumps fluid from a container to a therapy device to treat a patient. The fluid pump resides within a pump bay of the therapy delivery device. The fluid may be used to increase cool a tissue of the patient or clear debris. In one embodiment, generated signals may be delivered by a peripheral accessory connected to the generator through the connector board, and the generator may generate radio frequency (RF) energy for the purpose of prostate tissue ablation, where the effective ablation area of an electrode is increased by the fluid. In addition, the therapy delivery device may include a touch screen user interface, a visual operation indicator, a signal generator, and a removable connector board. | 03-10-2011 |
| 20110147046 | SELF EXPANDING ELECTRODE CUFF - An electrode lead assembly is described. The lead assembly includes an expandable cuff electrode that includes a series of spaced apart electrode elements and a substantially re-closable opening. | 06-23-2011 |
| 20110160827 | ELECTRODE LEAD SYSTEM - An electrode lead assembly includes a cuff electrode, a first lead portion and an anchor with the first lead portion having a length and a shape configured to provide strain relief on a nerve, on the cuff electrode, or on the first lead portion. | 06-30-2011 |
